Analyst Research

Report Title Price
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Depomed Inc Reaffirms FY 2013 Revenue Guidance

Wednesday, 7 Aug 2013 04:05pm EDT 

Depomed Inc announced that for fiscal 2013, it expects total revenues of approximately $125 to $135 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $127 million for fiscal 2013. 

Company Quote

-0.58 -5.30%
11:19am EDT